. (1977). Thorax, 32,[559][560][561][562]. Metabolic effects of intravenous salbutamol in the course of acute severe asthma. Peak expiratory flow rate and plasma free fatty acids, potassium, insulin, and glucose were measured in 10 patients admitted with acute severe asthma before and at frequent intervals for one hour after an infusion of salbutamol, 4 ,ug/kg over 10 minutes. These studies were repeated during the recovery phase and again before discharge. Effective bronchodilatation seen after the infusion was similar in the acute and recovery phases. Baseline plasma free fatty acids were elevated but rose significantly after the infusion. There was also a significant fall in plasma potassium. These changes occurred in all individuals. There were no significant differences in mean baseline or peak changes of plasma free fatty acids, potassium or insulin on any of the study days. There was no evidence of ,B receptor blockade in the acute phase in any patient.
Bronchodilators and corticosteroids are essential therapy in acute severe asthma. Since corticosteroids take several hours to produce their effects, the early use of bronchodilators is vital. Both inhaled and intravenous bronchodilators are commonly used, and recently intravenous salbutamol has been shown to be at least as effective as aminophylline (Williams et al., 1975; Johnson et al., 1976) . Moreover, there is evidence that, in patients with particularly severe attacks of asthma, the inhalational route is less effective than the intravenous (Williams and Seaton, 1977) .
The optimum dose of salbutamol is not yet established, although there is a tendency both in severe asthma and in obstetrics to use increasingly large doses (Liggins and Vaughan, 1973; May et al., 1975) .
After ,B sympathetic stimulation, elevation of plasma free fatty acid levels and a fall in plasma potassium as well as changes in insulin and glucose levels have been reported in normal subjects (Goldberg et al., 1975) and asthmatics (Tickner et al., 1977) . In view of the ,B stimulant effects of salbutamol it is important to establish whether its metabolic actions are likely to be of clinical significance in severe asthma.
We have therefore studied the effects of the intravenous administration of salbutamol to patients with severe acute asthma on admission and during recovery on plasma free fatty acids, potassium, insulin, and glucose.
Patients and methods
Ten patients with a severe acute exacerbation of asthma refractory to their usual trealtment ('status asthmaticus') gave informed consent to the study. All had previously demonstrated reversibility of airways obstruction, as measured by a greater than 15% improvement in peak expiratory flow rate (PEFR) with bronchodilators. All were admitted in a severe attack (pulse rate >110 per minute, PEFR <25% of predicted normal, Pao2<9 3 kPa (<70 mmHg)). Patients who had received parenteral sympathomimetics within two hours before admission and patients with diabetes mellitus or gross obesity were not included. Seven of the patients were on maintenance treatment with prednisone before admission.
Baseline observations of pulse rate, PEFR (as the best of three recordings with a Wright's peak flow meter), and arterial blood gases were made PEFRs too low to record on the peak flow meter were measured as 60 litres/minute. Plasma for estimation of free fatty acids (FFA) , glucose, insulin, and potassium was obtained.
Plasma free fatty acids were measured by the fluorimetric method of Carruthers and Young (1973) . Plasma insulin was measured by the double antibody technique and radioimmunoassay (Radiochemical Centre, Amersham) . Plasma potassium was measured by flame photometry, and glucose was estimated by ithe glucose oxidase method.
Salbutamol, 4 ,ug/kg, was given intravenously over 10 minutes by constant infusion pump. Serial measurements of PEFR and plasma for analysis were obtained at 5, 10, 15, 20, 30, 45, and 60 minutes after the beginning of infusion.
After initial investigations patients were started on a standard treatment with oxygen and hydrocortisone, 1 g immediately and 500 mg every six hours. Antibiotics were given when appropriate. Treatment with salbutamol, steroids, and oxygen was modified according to the patient's response during his stay in hospital.
The salbutamol infusion, as well as the measurements made previously, were repeated three days later and again before discharge. Bronchodilators were withheld for six hours, and patients were fasted overnight before each study. The results were analysed by Student's t test for paired samples.
Results

PEAK EXPIRATORY FLOW RATE
As expected, PEFR was lowest on admission and rose throughout hospitalisation in all patients.
Effective bronchodilatation, as measured by the mean maximum percentage increase in PEFR after the salbutamol infusion, was approximately 50% on each of the three days (Table 1) .
The onset of bronchodilatation occurred within five minutes, reaching a peak at 20±+ 11 minutes (mean-+SD). It fell thereafter to reach only 68% of the peak at 60 minutes.
FREE FATTY ACIDS
The mean baseline free fatty acid levels were raised on all three days, though at the time of (Dole, 1956) . However, the differences between mean baseline levels on the three study days were not significant ( (Table  4 ). There were no significant differences between the mean peak values obtained on any day. The mean time taken to reach peak plasma insulin was 14+4-8 minutes.
GLUCOSE
As patients on admission had not been fasting, the mean baseline plasma glucose was slightly higher on admission than on subsequent days (P<005). After the infusion of salbutamol there was no significant rise in plasma glucose.
Discussion
Intravenous salbutamol has been shown previously to cause a rise in free fatty acids, insulin, and glucose and a fall in potassium in normal subjects (Goldberg et al., 1975; Leitch et al., 1976) . There have been very few previous studies of the metabolic changes in acute severe asthma. Tickner et al. (1977) showed a profound metabolic disturbance in patients admitted in acute severe asthma but demonstrated no significant changes in free fatty acids, insulin or glucose after a combination of intravenous aminophylline with an infusion of salbutamol at 10 pg/minute. Neville et al. (1977) showed that stable asthmatics given intravenous salbutamol, 4 pg/kg over 5 minutes, had a significant rise in plasma glucose and insulin and a fall in plasma potassium. They also showed raised baseline free fatty acid levels without a further significant rise after the salbutamol infusion. However, the free fatty acids were estimated for only 10 minutes after infusion.
Our results differ in that we have shown significant rises in free fatty acids and insulin after a 10-minute infusion of salbutamol, 4 jug/kg. These differences may relate to the different rates of administration and the timing of measurements. Moreover, while initial levels of free fatty acids were raised in our patients, in keeping with the metabolic response to the stress of their illness, fasting levels had still not fallen to within the normal range at the time of discharge.
It is recognised that in acute myocardial infarction arrhythmias may be associated with high levels of free fatty acids (Oliver et al., 1968; Rutenberg et al., 1969) . While the situation in acute asthma is different, in that the myocardium is usually normal, there remains the theoretical danger of precipitation of arrhythmias by sympathetic stimulation coupled with hypoxaemia. Moreover, there is a well-recognised danger of hypokalaemia in the treatment of severe asthma with high-dose corticosteroids which may be made worse with salbutamol administration. While, in our experience, arrhythmias have not been a feature of the use of intravenous salbutamol, we feel that further studies of the dose and method of administration of this drug should take account of the possibility. In addition, it remains essential to monitor potassium in the management of this disease.
In this study no patient failed to respond to intravenous salbutamol, either by a rise in peak flow rate or by metabolic changes. This accords with our previous experience that ,B receptor blockade rarely occurs in acute severe asthma (Williams et al., 1975; Williams and Seaton, 1977) . 
